RMD gears up for fiscal Q3 earnings with steady estimates, rising demand in sleep devices and AI-driven digital health tools ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

ResMed is on a mission to cement the lead it’s built while competitor Philips has been out of the CPAP machine-making game. That process of building out its market share for the long-term has recently ...

RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.

ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, ...

As it continues to take advantage of the gaping hole left in the CPAP machine market by competitor Philips’ ongoing respiratory recall troubles, ResMed is still fine-tuning its long-term growth ...

ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, ...

Healthcare device sector dynamics continue to evolve amid changing clinical demand patterns; ResMed maintains operational momentum supported by product innovation and ...

ResMed is the global leader in the sleep apnea market. Sales growth accelerated during COVID and again recently as a result of a product recall from its major competitor. Despite a strong last quarter ...

Medical equipment maker ResMed will pay $37.5 million to resolve allegations brought by the Department of Justice (DOJ) that it paid kickbacks to durable medical equipment suppliers, sleep labs and ...

ResMed’s voluntary recall of some of its CPAP mask magnets has now been labeled as Class I by FDA. The agency announced the classification late last week. In November, ResMed began recalling some ...